Prescription Drug Price Transparency
Related Sites
Prescription Drug Price Transparency
Public Interest Drug Lists
The Minnesota Legislature expanded the Minnesota Prescription Drug Price Transparency Act in 2023 to include reporting from drug manufacturers, pharmacy benefit managers, wholesalers, and pharmacies on drugs of substantial public interest. The Minnesota Department of Health (MDH) is responsible for producing and publicly posting quarterly lists of the prescription drugs requiring reporting.
Invitation to comment on draft methodology
On April 23, MDH released draft methodology for the inaugural list of drugs of substantial public interest to invite public feedback. During a two-week comment period, MDH welcomes feedback on the draft methodology, as well as suggestions on other areas of the drug market affecting Minnesotans that MDH should explore in future lists.
- Draft Methodology of Drugs of Substantial Public Interest Reporting (PDF), April 2024
Stakeholders may submit comments by emailing health.Rx@state.mn.us or through submission of the Public Input on Prescription Drug Price Transparency in Minnesota form by 4 p.m. CT on May 9, 2024.
MDH will release the final list for data collection in late spring of 2024.
Future lists
MDH will continue to seek public input, using various strategies, for future lists and expects to adjust the release of subsequent lists to ensure no more than one list is released quarterly. Reporting entities will have approximately 90 days to report after each list is released (notifications will be sent 30 or more days after the list is released; reports are due 60 days after notifications are sent).
The Minnesota Department of Health (MDH) wants to hear from you!
Have prescription drug prices impacted your health care? What do you think is creating affordability challenges for patients? What drugs – and their prices – have a substantial public interest and would benefit from pricing transparency?
By completing the Public Input on Prescription Drug Price Transparency in Minnesota form, you can: share your experiences and suggest where you think MDH should focus its drug price transparency work.